Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR^WT, EGFR^T790M, and EGFR^L858R)

References

• Kothayer H, Rezq S, Abdelkhalek AS, Romero DG, Elbaramawi SS. Triple targeting of mutant EGFRL858R/T790M, COX-2, and 15-LOX: design and synthesis of novel quinazolinone tethered phenyl urea derivatives for anti-inflammatory and anticancer evaluation. J Enzyme Inhib Med Chem. 2023;38(1):2199166.
   PubMed Web of Science ®Google Scholar
• Engle K, Kumar G. Cancer multidrug-resistance reversal by ABCB1 inhibition: a recent update. Eur J Med Chem. 2022;239:114542.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhao Y, Liu S, Zhang J, Assaraf YG, Cui W, Wang L. Epigenetic enzyme mutations as mediators of anti-cancer drug resistance. Drug Resist Updates. 2022;61:100821.
   PubMed Web of Science ®Google Scholar
• Wang Z, Cai J, Cheng J, Yang W, Zhu Y, Li H, Lu T, Chen Y, Lu S. FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance. J Med Chem. 2021;64(6):2878–2900.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249.
   PubMed Web of Science ®Google Scholar
• Wu M, Zhang P. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance. Cancer Lett. 2020;469:207–216.
   PubMed Web of Science ®Google Scholar
• El-Haggar R, Hammad SF, Alsantali RI, Alrooqi MM, El Hassab MA, Masurier N, Ahmed MF. 3-Substituted-2,3-dihydrothiazole as a promising scaffold to design EGFR inhibitors. Bioorg Chem. 2022;129:106172.
   PubMed Web of Science ®Google Scholar
• Ahmed SA, Kamel MS, Aboelez MO, Ma X, Al-Karmalawy AA, Mousa SAS, Shokr EK, Abdel-Ghany H, Belal A, El Hamd MA, et al. Thieno [2, 3-b] thiophene derivatives as potential EGFRWT and EGFRT790M inhibitors with antioxidant activities: microwave-assisted synthesis and quantitative in vitro and in silico studies. ACS Omega. 2022;7(49):45535–45544.
   PubMed Web of Science ®Google Scholar
• Hong SY, Kao YR, Lee TC, Wu CW. Upregulation of E3 ubiquitin ligase CBLC enhances EGFR dysregulation and signaling in lung adenocarcinomaCBLC dysregulates EGFR signaling. Cancer Res. 2018;78(17):4984–4996.
   PubMed Web of Science ®Google Scholar
• Jänne PA, Baik C, Su W-C, Johnson ML, Hayashi H, Nishio M, Kim D-W, Koczywas M, Gold KA, Steuer CE, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor–resistant, EGFR-mutated non–small cell lung cancer. Cancer Discov. 2022;12(1):74–89.
   PubMed Web of Science ®Google Scholar
• Lieser RM, Li Q, Chen W, Sullivan MO. Incorporation of endosomolytic peptides with varying disruption mechanisms into EGFR-Targeted protein conjugates: the effect on intracellular protein delivery and EGFR specificity in breast cancer cells. Mol Pharm. 2022;19(2):661–673.
   PubMedGoogle Scholar
• Farag AK, Ahn BS, Yoo JS, Karam R, Roh EJ. Design, synthesis, and biological evaluation of pseudo-bicyclic pyrimidine-based compounds as potential EGFR inhibitors. Bioorg Chem. 2022;126:105918.
   PubMed Web of Science ®Google Scholar
• El-Naggar AM, Hassan A, Elkaeed EB, Alesawy MS, Al‐Karmalawy AA. Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2. Bioorg Chem. 2022;123:105770.
   PubMed Web of Science ®Google Scholar
• de Lima PO, Joseph S, Panizza B, Simpson F. Epidermal growth factor receptor’s function in cutaneous squamous cell carcinoma and its role as a therapeutic target in the age of immunotherapies. Curr Treat Options Oncol. 2020;21(1):9.
   PubMed Web of Science ®Google Scholar
• Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022;19(8):499–514.
   PubMed Web of Science ®Google Scholar
• Gelatti AC, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC. Lung Cancer. 2019;137:113–122.
   PubMed Web of Science ®Google Scholar
• Liang H, Pan Z, Wang W, Guo C, Chen D, Zhang J, Zhang Y, Tang S, He J, Liang W. The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis. J Thorac Dis. 2018;10(4):2311–2320.
   PubMed Web of Science ®Google Scholar
• Qin X, Liu P, Li Y, Hu L, Liao Y, Cao T, Yang L. Design, synthesis and biological evaluation of novel 3, 4-dihydro-2H-[1, 4] oxazino [2, 3-f] quinazolin derivatives as EGFR-TKIs. Bioorg Med Chem Lett. 2023;80:129104.
   PubMed Web of Science ®Google Scholar
• Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL, Bian J, Xia YZ, Kong LY. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: from molecular mechanisms to clinical research. Pharmacol Res. 2021;167:105583.
   PubMed Web of Science ®Google Scholar
• Beyett TS, To C, Heppner DE, Rana JK, Schmoker AM, Jang J, De Clercq DJH, Gomez G, Scott DA, Gray NS, et al. Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors. Nat Commun. 2022;13(1):2530–2543.
   PubMed Web of Science ®Google Scholar
• Saad MH, El-Moselhy TF, Nabaweya E-DS, Mehany AB, Belal A, Abourehab MA, Tawfik HO, El-Hamamsy MH. Discovery of new symmetrical and asymmetrical nitrile-containing 1, 4-dihydropyridine derivatives as dual kinases and P-glycoprotein inhibitors: synthesis, in vitro assays, and in silico studies. J Enzyme Inhib Med Chem. 2022;37(1):2489–2511.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, El Hassab MA, Elsayed ZM, Al-Warhi T, Elkady H, Abo-Ashour MF, Abourehab MA, Eissa IH, Abdel-Aziz HA. Design, synthesis, in vitro biological assessment and molecular modeling insights for novel 3-(naphthalen-1-yl)-4, 5-dihydropyrazoles as anticancer agents with potential EGFR inhibitory activity. Sci Rep. 2022;12(1):12821.
   PubMed Web of Science ®Google Scholar
• Nafie MS, Kishk SM, Mahgoub S, Amer AM. Quinoline‐based thiazolidinone derivatives as potent cytotoxic and apoptosis‐inducing agents through EGFR inhibition. Chem Biol Drug Des. 2022;99(4):547–560.
   PubMed Web of Science ®Google Scholar
• Eissa IH, Yousef RG, Elkady H, Alsfouk AA, Alsfouk BA, Husein DZ, Ibrahim IM, Elkaeed EB, Metwaly AM. A new anticancer semisynthetic theobromine derivative targeting EGFR protein: CADDD study. Life. 2023;13(1):191.
   PubMedGoogle Scholar
• Kumari L, Mazumder A, Pandey D, Yar MS, Kumar R, Mazumder R, Sarafroz M, Ahsan MJ, Kumar V, Gupta S, et al. Synthesis and biological potentials of quinoline analogues: a review of literature. Mini-Rev Organ Chem. 2019;16(7):653–688.
   Web of Science ®Google Scholar
• Faidallah HM, Rostom SA, Asiri AM, Khan KA, Radwan MF, Asfour HZ. 3-Cyano-8-methyl-2-oxo-1, 4-disubstituted-1, 2, 5, 6, 7, 8-hexahydroquinolines: synthesis and biological evaluation as antimicrobial and cytotoxic agents. J Enzyme Inhib Med Chem. 2013;28(1):123–130.
   PubMed Web of Science ®Google Scholar
• Al-Said MS, Ghorab MM, Al-Dosari MS, Hamed MM. Synthesis and in vitro anticancer evaluation of some novel hexahydroquinoline derivatives having a benzenesulfonamide moiety. Eur J Med Chem. 2011;46(1):201–207.
   PubMed Web of Science ®Google Scholar
• Sabbagh OIE, Shabaan MA, Kadry HH, Al‐Din ES. Synthesis of new nonclassical acridines, quinolines, and quinazolines derived from dimedone for biological evaluation. Arch Pharm . 2010;343(9):519–527.
   PubMed Web of Science ®Google Scholar
• Shaheen MA, El-Emam AA, El-Gohary NS. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M. Bioorg Chem. 2020;105:104274.
   PubMed Web of Science ®Google Scholar
• Ranjbar S, Edraki N, Firuzi O, Khoshneviszadeh M, Miri R. 5-Oxo-hexahydroquinoline: an attractive scaffold with diverse biological activities. Mol Divers. 2019;23(2):471–508.
   PubMed Web of Science ®Google Scholar
• Roskoski R. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2019;139:395–411.
   PubMed Web of Science ®Google Scholar
• Laudadio E, Mobbili G, Sorci L, Galeazzi R, Minnelli C. Mechanistic insight toward EGFR activation induced by ATP: role of mutations and water in ATP binding patterns. J Biomol Struct Dyn. 2023;41(14):6492–6501.
   PubMed Web of Science ®Google Scholar
• Sabbah DA, Hajjo R, Sweidan K. Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr Top Med Chem. 2020;20(10):815–834.
   PubMed Web of Science ®Google Scholar
• To C, Beyett TS, Jang J, Feng WW, Bahcall M, Haikala HM, Shin BH, Heppner DE, Rana JK, Leeper BA, et al. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nat Cancer. 2022;3(4):402–417.
   PubMedGoogle Scholar
• Abdullah MiN, Ali Y, Abd Hamid S. Insights into the structure and drug design of benzimidazole derivatives targeting the epidermal growth factor receptor (EGFR). Chem Biol Drug Des. 2022;100(6):921–934.
   PubMed Web of Science ®Google Scholar
• Jiao X, Zhang Q, Zhang Y, Shao J, Ding L, Tang C, Feng B. Synthesis and biological evaluation of new series of quinazoline derivatives as EGFR/HER2 dual-target inhibitors. Bioorg Med Chem Lett. 2022;67:128703.
   PubMed Web of Science ®Google Scholar
• Zubair T, Bandyopadhyay D. Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities. Int J Mol Sci. 2023;24(3):2651–2676.
   PubMed Web of Science ®Google Scholar
• Todsaporn D, Mahalapbutr P, Poo-Arporn RP, Choowongkomon K, Rungrotmongkol T. Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR. Comput Biol Med. 2022;147:105787.
   PubMed Web of Science ®Google Scholar
• Aly RM, Serya RA, El-Motwally AM, Esmat A, Abbas S, Abou El Ella DA. Novel quinoline-3-carboxamides (part 2): design, optimization and synthesis of quinoline based scaffold as EGFR inhibitors with potent anticancer activity. Bioorg Chem. 2017;75:368–392.
   PubMed Web of Science ®Google Scholar
• Gaber AA, Morsy AME, ‐ Sherbiny FF, Bayoumi AH, Gamal KME, ‐ Adl KE, ‐ Al‐Karmalawy AA, Ezz Eldin RR, Saleh MA, Abulkhair HS. Pharmacophore‐linked pyrazolo [3, 4‐d] pyrimidines as EGFR‐TK inhibitors: synthesis, anticancer evaluation, pharmacokinetics, and in silico mechanistic studies. Arch Pharm. 2021;354:e2100258.
   Google Scholar
• Shaikh GM, Murahari M, Thakur S, Kumar MS, Yc M. Studies on ligand-based pharmacophore modeling approach in identifying potent future EGFR inhibitors. J Mol Graph Model. 2022;112:108114.
   PubMed Web of Science ®Google Scholar
• Sangani CB, Makawana JA, Zhang X, Teraiya SB, Lin L, Zhu H-L. Design, synthesis and molecular modeling of pyrazole–quinoline–pyridine hybrids as a new class of antimicrobial and anticancer agents. Eur J Med Chem. 2014;76:549–557.
   PubMed Web of Science ®Google Scholar
• Rao K, Chai Z, Zhou P, Liu D, Sun Y, Yu F. Transition-metal-free approach to quinolines via direct oxidative cyclocondensation reaction of N, N-dimethyl enaminones with o-aminobenzyl alcohols. Front Chem. 2022;10:1008568.
   PubMed Web of Science ®Google Scholar
• Amorzesh H, Bayat M, Nasri S. Catalyst-free synthesis of highly functionalized triazole hexahydroquinoline carbohydrazide scaffolds via four-component cyclocondensation reaction. Mol Diversity. 2022;26:1–10.
   PubMedGoogle Scholar
• Kalhor S, Yarie M, Rezaeivala M, Zolfigol MA. Novel magnetic nanoparticles with morpholine tags as multirole catalyst for synthesis of hexahydroquinolines and 2-amino-4, 6-diphenylnicotinonitriles through vinylogous anomeric-based oxidation. Res Chem Intermed. 2019;45(6):3453–3480.
   Web of Science ®Google Scholar
• Modha SG, Pöthig A, Dreuw A, Bach T. 6π] Photocyclization to cis-hexahydrocarbazol-4-ones: substrate modification, mechanism, and scope. J Org Chem. 2019;84(3):1139–1153.
   PubMed Web of Science ®Google Scholar
• Mousavi SR, Sereshti H, Rashidi Nodeh H, Foroumadi A. A novel and reusable magnetic nanocatalyst developed based on graphene oxide incorporated strontium nanoparticles for the facial synthesis of β‐enamino ketones under solvent‐free conditions. Appl Organometal Chem. 2019;33(1):e4644.
   Web of Science ®Google Scholar
• Nonsuwan P, Matsugami A, Hayashi F, Hyon S-H, Matsumura K. Controlling the degradation of an oxidized dextran-based hydrogel independent of the mechanical properties. Carbohydr Polym. 2019;204:131–141.
   PubMed Web of Science ®Google Scholar
• Kumar AR, Selvaraj S, Jayaprakash K, Gunasekaran S, Kumaresan S, Devanathan J, Selvam K, Ramadass L, Mani M, Rajkumar P. Multi-spectroscopic (FT-IR, FT-Raman, 1H NMR and 13C NMR) investigations on syringaldehyde. J Mol Struct. 2021;1229:129490.
   Web of Science ®Google Scholar
• Hussen AS, Pandey AP, Sharma A. Mechanochemical-(hand-grinding-) assisted domino synthesis of fused pyran-spirooxindoles under solvent‐and catalyst‐free condition. ChemistrySelect. 2018;3(41):11505–11509.
   Web of Science ®Google Scholar
• Hansen PE, Vakili M, Kamounah FS, Spanget-Larsen J. NH stretching frequencies of intramolecularly hydrogen-bonded systems: an experimental and theoretical study. Molecules. 2021;26:1–19.
   Web of Science ®Google Scholar
• Shaldam M, Tawfik H, Elmansi H, Belal F, Yamaguchi K, Sugiura M, Magdy G. Synthesis, crystallographic, DNA binding, and molecular docking/dynamic studies of a privileged chalcone-sulfonamide hybrid scaffold as a promising anticancer agent. J Biomol Struct Dyn. 2022;40:1–15.
   PubMedGoogle Scholar
• Babar A, Saeed A, Fatima S, Bolte M, Arshad N, Parveen U, Hökelek T, El-Seedi HR. Synthesis, X-ray, DFT, Hirshfeld surface analysis, molecular docking, urease inhibition, antioxidant, cytotoxicity, DNA protection, and DNA binding properties of 5-(tert-butyl)-N-(2, 4-dichlorophenyl)-1 H-1, 2, 4-triazol-3-amine. Struct Chem. 2023;34:1–17.
   Google Scholar
• Mishnev A, Bisenieks E, Mandrika I, Petrovska R, Kalme Z, Bruvere I, Duburs G. Crystal structure and metabolic activity of 4-(thien-2-yl)-2-methyl-5-oxo-1, 4, 5, 6, 7, 8-hexahydroquinoline-3-carboxylic acid ethoxycarbonylphenylmethylester. Acta Crystallogr E Crystallogr Commun. 2018;74(Pt 11):1577–1579.
   PubMedGoogle Scholar
• Gündüz MG, Armaković SJ, Dengiz C, Tahir MN, Armaković S. Crystal structure determination and computational studies of 1, 4-dihydropyridine derivatives as selective T-type calcium channel blockers. J Mol Struct. 2021;1230:129898.
   Web of Science ®Google Scholar
• Tawfik HO, Petreni A, Supuran CT, El-Hamamsy MH. Discovery of new carbonic anhydrase IX inhibitors as anticancer agents by toning the hydrophobic and hydrophilic rims of the active site to encounter the dual-tail approach. Eur J Med Chem. 2022;232:114190.
   PubMed Web of Science ®Google Scholar
• Mar’yasov M, Sheverdov V, Davydova V, Nasakin O. Antiproliferative activity of cyano-substituted pyrans and 1, 2, 5, 6, 7, 8-hexahydroquinoline-3, 3, 4, 4-tetracarbonitriles. Pharm Chem J. 2017;50(12):798–799.
   Web of Science ®Google Scholar
• Kim E, Chung Y. Feasibility study of deep learning based radiosensitivity prediction model of National Cancer Institute-60 cell lines using gene expression. Nuclear Eng Technol. 2022;54(4):1439–1448.
   Web of Science ®Google Scholar
• Ciftci H, Sever B, Ocak F, Bayrak N, Yıldız M, Yıldırım H, DeMirci H, Tateishi H, Otsuka M, Fujita M. In vitro and in silico study of analogs of plant product plastoquinone to be effective in colorectal cancer treatment. Molecules. 2022;27:693–711.
   PubMed Web of Science ®Google Scholar
• Sonousi A, Hassan RA, Osman EO, Abdou AM, Emam SH. Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity. J Enzyme Inhib Med Chem. 2022;37(1):2644–2659.
   PubMedGoogle Scholar
• Aboukhatwa SM, Sidhom PA, Angeli A, Supuran CT, Tawfik HO. Terminators or guardians? Design, synthesis, and cytotoxicity profiling of chalcone-sulfonamide hybrids. ACS Omega. 2023;8(8):7666–7683.
   PubMedGoogle Scholar
• Zhou Y, Xiang S, Yang F, Lu X. Targeting gatekeeper mutations for kinase drug discovery. J Med Chem. 2022;65(23):15540–15558.
   PubMed Web of Science ®Google Scholar
• Wang J, Wu L. An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer. Expert Opin Pharmacother. 2022;23(6):647–652.
   PubMed Web of Science ®Google Scholar
• Gad MM, Abdelwaly A, Helal MA. Structural basis for the selectivity of 3rd generation EGFR inhibitors: a molecular dynamics study. J Biomol Struct Dyn. 2023;41(13):6134–6144.
   PubMed Web of Science ®Google Scholar
• You L, Zheng X, Deng D, Pan H, Han W. The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study. Sci Rep. 2022;12(1):14624.
   PubMed Web of Science ®Google Scholar
• Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007;11(3):217–227.
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, et al. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir Med. 2022;10(1):72–82.
   PubMed Web of Science ®Google Scholar
• Huang CH, Ju JS, Chiu TH, Huang ACC, Tung PH, Wang CC, Liu CY, Chung FT, Fang YF, Guo YK, et al. Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation. Int J Cancer. 2022;150(4):626–635.
   PubMed Web of Science ®Google Scholar
• Kenessey I, Kramer Z, István L, Cserepes MT, Garay T, Hegedűs B, Dobos J, Tímár J, Tóvári J. Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model. Melanoma Res. 2018;28(6):536–546.
   PubMed Web of Science ®Google Scholar
• Xuhong JC, Qi XW, Zhang Y, Jiang J. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. Am J Cancer Res. 2019;9:2103–2119.
   PubMed Web of Science ®Google Scholar
• Necchi A, Lo Vullo S, Perrone F, Raggi D, Giannatempo P, Calareso G, Nicolai N, Piva L, Biasoni D, Catanzaro M, et al. First‐line therapy with dacomitinib, an orally available pan‐HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open‐label, single‐arm, single‐centre, phase 2 study. BJU Int. 2018;121(3):348–356.
   PubMed Web of Science ®Google Scholar
• Takeda M, Nakagawa K. First-and second-generation EGFR-TKIs are all replaced to osimertinib in chemo-naive EGFR mutation-positive non-small cell lung cancer? Int J Mol Sci. 2019;20:146–164.
   PubMed Web of Science ®Google Scholar
• Lazzari C, Gregorc V, Karachaliou N, Rosell R, Santarpia M. Mechanisms of resistance to osimertinib. J Thorac Dis. 2020;12(5):2851–2858.
   PubMed Web of Science ®Google Scholar
• Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, Lopez-Diaz FJ, Lippman SM, Husain H. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Res. 2019;79(4):689–698.
   PubMed Web of Science ®Google Scholar
• Zhang W, Fan YF, Cai CY, Wang JQ, Teng QX, Lei ZN, Zeng L, Gupta P, Chen ZS. Olmutinib (BI1482694/HM61713), a novel epidermal growth factor receptor tyrosine kinase inhibitor, reverses ABCG2-mediated multidrug resistance in cancer cells. Front Pharmacol. 2018;9:1097. 1–13.
   PubMed Web of Science ®Google Scholar
• Zhao S, Liu J, Lv Z, Zhang G, Xu Z. Recent updates on 1,2,3-triazole-containing hybrids with in vivo therapeutic potential against cancers: a mini-review. Eur J Med Chem. 2023;251:115254.
   PubMed Web of Science ®Google Scholar
• Kesavan MP, Ravi L, Balachandran C, Thangadurai TD, Aoki S, Webster TJ, Rajesh J. Promising anticancer activity with high selectivity of DNA/plasma protein targeting new phthalazin-1(2H)-one heterocyclic scaffolds. J Mol Struct. 2023;1274:134423. 1–12.
   Web of Science ®Google Scholar
• El-Malah A, Taher ES, Angeli A, Elbaramawi SS, Mahmoud Z, Moustafa N, Supuran CT, Ibrahim TS. Schiff bases as linker in the development of quinoline-sulfonamide hybrids as selective cancer-associated carbonic anhydrase isoforms IX/XII inhibitors: a new regioisomerism tactic. Bioorg Chem. 2023;131:106309.
   PubMed Web of Science ®Google Scholar
• He X, Chen J, Wei L, Kandawa-Shultz M, Shao G, Wang Y. Antitumor activity of iridium/ruthenium complexes containing nitro-substituted quinoline ligands in vivo and in vitro. Dyes Pigm. 2023;213:111146.
   Web of Science ®Google Scholar
• Cao TQ, An HX, Ma RJ, Dai KY, Ji HY, Liu AJ, Zhou JP. Structural characteristics of a low molecular weight velvet antler protein and the anti-tumor activity on S180 tumor-bearing mice. Bioorg Chem. 2023;131:106304.
   PubMed Web of Science ®Google Scholar
• Hammouda MM, Elmaaty AA, Nafie MS, Abdel-Motaal M, Mohamed NS, Tantawy MA, Belal A, Alnajjar R, Eldehna WM, Al‐Karmalawy AA. Design and synthesis of novel benzoazoninone derivatives as potential CBSIs and apoptotic inducers: in vitro, in vivo, molecular docking, molecular dynamics, and SAR studies. Bioorg Chem. 2022;127:105995.
   PubMed Web of Science ®Google Scholar
• Amin MM, Abuo-Rahma GEDA, Shaykoon MSA, Marzouk AA, Abourehab MA, Saraya RE, Badr M, Sayed AM, Beshr EA. Design, synthesis, cytotoxic activities, and molecular docking of chalcone hybrids bearing 8-hydroxyquinoline moiety with dual tubulin/EGFR kinase inhibition. Bioorg Chem. 2023;134:106444.
   PubMed Web of Science ®Google Scholar
• Hegedüs L, Okumus Ö, Mairinger F, Ploenes T, Reuter S, Schuler M, Welt A, Vega-Rubin-de-Celis S, Theegarten D, Bankfalvi A, et al. TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy. Lung Cancer. 2023;178:237–246.
   PubMed Web of Science ®Google Scholar
• Hinterleitner C, Strähle J, Malenke E, Hinterleitner M, Henning M, Seehawer M, Bilich T, Heitmann J, Lutz M, Mattern S, et al. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat Commun. 2021;12(1):7005.
   PubMed Web of Science ®Google Scholar
• Noser AA, Abdelmonsef AH, Salem MM. Design, synthesis and molecular docking of novel substituted azepines as inhibitors of PI3K/Akt/TSC2/mTOR signaling pathway in colorectal carcinoma. Bioorg Chem. 2023;131:106299.
   PubMed Web of Science ®Google Scholar
• Ma K, Wang Z, Ju X, Huang J, He R. Rapeseed peptide inhibits HepG2 cell proliferation by regulating the mitochondrial and P53 signaling pathways. J Sci Food Agric. 2023;103(3):1474–1483.
   PubMed Web of Science ®Google Scholar
• Teleb WK, Tantawy MA, Xu X, Hussein AA, Abdel-Rahman MA. Cytotoxicity and molecular alterations induced by scorpion venom antimicrobial peptide Smp43 in breast cancer cell lines MDA-MB-231 and MCF-7. Int J Pept Res Ther. 2022;29(1):15.
   Web of Science ®Google Scholar
• Swedan HK, Kassab AE, Gedawy EM, Elmeligie SE. Design, synthesis, and biological evaluation of novel ciprofloxacin derivatives as potential anticancer agents targeting topoisomerase II enzyme. J Enzyme Inhib Med Chem. 2023;38(1):118–137.
   PubMed Web of Science ®Google Scholar
• Mir SA, Muhammad A, Padhiary A, Ekka NJ, Baitharu I, Naik PK, Nayak B. Identification of potent EGFR-TKD inhibitors from NPACT database through combined computational approaches. J Biomol Struct Dyn. 2023;41:1–14.
   PubMedGoogle Scholar
• Khan S, Hussain A, Asif M, Sattar FA, Audhal FA, Qadir MI, Hamdard MH., Nasrullah   In-silico studies of inhibitory compounds against protease enzymes of SARS-CoV-2. Medicine . 2023;102(6):e31318.
   PubMed Web of Science ®Google Scholar
• Musa A, Ihmaid SK, Hughes DL, Said MA, Abulkhair HS, El-Ghorab AH, Abdelgawad MA, Shalaby K, Shaker ME, Alharbi KS, et al. The anticancer and EGFR-TK/CDK-9 dual inhibitory potentials of new synthetic pyranopyrazole and pyrazolone derivatives: x-ray crystallography, in vitro, and in silico mechanistic investigations. J Biomol Struct Dyn. 2023;41:1–15.
   PubMed Web of Science ®Google Scholar
• Kardile RA, Sarkate AP, Lokwani DK, Tiwari SV, Azad R, Thopate SR. Thopate, Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: in vitro screening and ADME predictions. Eur J Med Chem. 2023;245(Pt 1):114889.
   PubMedGoogle Scholar
• Adel M, Abouzid KA. New fluorinated diarylureas linked to pyrrolo [2, 3-d] pyrimidine scaffold as VEGFR-2 inhibitors: molecular docking and biological evaluation. Bioorg Chem. 2022;127:106006.
   PubMed Web of Science ®Google Scholar
• Paul SK, Dutta Chowdhury K, Dey SR, Paul A, Haldar R. Exploring the possibility of drug repurposing for cancer therapy targeting human lactate dehydrogenase A: a computational approach. J Biomol Struct Dyn. 2022;40:1–10.
   PubMedGoogle Scholar
• El-Gazzar YI, Ghaiad HR, El Kerdawy AM, George RF, Georgey HH, Youssef KM, El‐Subbagh HI. New quinazolinone‐based derivatives as DHFR/EGFR‐TK inhibitors: synthesis, molecular modeling simulations, and anticancer activity. Arch Pharm . 2023;356(1):e2200417.
   PubMed Web of Science ®Google Scholar
• Songtawee N, Gleeson MP, Choowongkomon K. Computational study of EGFR inhibition: molecular dynamics studies on the active and inactive protein conformations. J Mol Model. 2013;19(2):497–509.
   PubMed Web of Science ®Google Scholar
• Ahmad I, Shaikh M, Surana S, Ghosh A, Patel H. p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor. J Biomol Struct Dyn. 2022;40(7):3046–3059.
   PubMed Web of Science ®Google Scholar
• Al-Warhi T, El Kerdawy AM, Said MA, Albohy A, Elsayed ZM, Aljaeed N, Elkaeed EB, Eldehna WM, Abdel-Aziz HA, Abdelmoaz MA. Novel 2-(5-Aryl-4, 5-dihydropyrazol-1-yl) thiazol-4-one as EGFR inhibitors: synthesis, biological assessment and molecular docking insights. Drug Des Devel Ther. 2022;16:1457–1471.
   PubMed Web of Science ®Google Scholar
• Ghorab WM, El-Sebaey SA, Ghorab MM. Design, synthesis and molecular modeling study of certain EGFR inhibitors with a quinazolinone scaffold as anti-hepatocellular carcinoma and Radio-sensitizers. Bioorg Chem. 2023;131:106310.
   PubMed Web of Science ®Google Scholar
• Shao J, Zhu K, Du D, Zhang Y, Tao H, Chen Z, Jiang H, Chen K, Luo C, Duan W. Discovery of 2-substituted-N-(3-(3, 4-dihydroisoquinolin-2 (1H)-yl)-2-hydroxypropyl)-1, 2, 3, 4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: design, synthesis and biological evaluation. Eur J Med Chem. 2019;164:317–333.
   PubMed Web of Science ®Google Scholar
• Bugge S, Moen IU, Sylte KOK, Sundby E, Hoff BH. Truncated structures used in search for new lead compounds and in a retrospective analysis of thienopyrimidine-based EGFR inhibitors. Eur J Med Chem. 2015;94:175–194.
   PubMed Web of Science ®Google Scholar
• Zhang C, Pei H, He J, Zhu J, Li W, Niu T, Xiang M, Chen L. Design, synthesis and evaluation of novel 7H-pyrrolo [2, 3-d] pyrimidin-4-amine derivatives as potent, selective and reversible Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis. Eur J Med Chem. 2019;169:121–143.
   PubMed Web of Science ®Google Scholar
• Tawfik HO, El-Moselhy TF, El-Din NS, El-Hamamsy MH. Design, synthesis, and bioactivity of dihydropyrimidine derivatives as kinesin spindle protein inhibitors. Bioorg Med Chem. 2019;27(23):115126.
   PubMed Web of Science ®Google Scholar
• Chinen AB, Guan CM, Ferrer JR, Barnaby SN, Merkel TJ, Mirkin CA. Nanoparticle probes for the detection of cancer biomarkers, cells, and tissues by fluorescence. Chem Rev. 2015;115(19):10530–10574.
   PubMed Web of Science ®Google Scholar
• Sordon S, Popłoński J, Milczarek M, Stachowicz M, Tronina T, Kucharska AZ, Wietrzyk J, Huszcza E. Structure–antioxidant–antiproliferative activity relationships of natural C7 and C7–C8 hydroxylated flavones and flavanones. Antioxidants. 2019;8(7):210.
   Web of Science ®Google Scholar
• Nasser AA, Eissa IH, Oun MR, El-Zahabi MA, Taghour MS, Belal A, Saleh AM, Mehany ABM, Luesch H, Mostafa AE, et al. Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR WT and EGFR T790M. Org Biomol Chem. 2020;18(38):7608–7634.
   PubMed Web of Science ®Google Scholar
• Mghwary AE-S, Gedawy EM, Kamal AM, Abuel-Maaty SM. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile. J Enzyme Inhib Med Chem. 2019;34(1):838–852.
   PubMed Web of Science ®Google Scholar
• Behzadi M, Eghtedardoost M, Bagheri M. Endocytosis involved d-oligopeptide of tryptophan and arginine displays ordered nanostructures and cancer cell stereoselective toxicity by autophagy. ACS Appl Mater Interfaces. 2022;14(13):14928–14943.
   PubMed Web of Science ®Google Scholar
• Mir SA, Dash GC, Meher RK, Mohanta PP, Chopdar KS, Mohapatra PK, Baitharu I, Behera AK, Raval MK, Nayak B. In silico and in vitro evaluations of fluorophoric thiazolo-[2, 3-b] quinazolinones as anti-cancer agents targeting EGFR-TKD. Appl Biochem Biotechnol. 2022;194(10):4292–4318.
   PubMed Web of Science ®Google Scholar
• Ezelarab HA, Ali TF, Abbas SH, Sayed AM, Beshr EA, Hassan HA. New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization. Mol Divers. 2023;27:1–18.
   PubMedGoogle Scholar